MOESM10 of Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer

Additional file 10: Overall survival analysis of metastatic breast cancer patients, showing the p-value, Hazard ratio and the 95% confidence interval for this Hazard ratio. Comparison of joint analysis of new blood biomarkers (CTCs and cfDNA) against traditional biomarkers (CA15-3 and AP). Stratified biomarkers as variables. Overall survival population results from joint analysis of biomarkers.